Governors Lane’s Cerevel Therapeutics Holdings, Inc. Common Stock CERE Stock Holding History

Governors Lane’s Portfolio CERE Stock Details CERE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-192,700	Closed	-$7.88M	–	79
2024 Q2	$7.88M	Buy	+192,700	New	+$8.02M	0.66%	39
2024 Q1	–	Sell	-364,400	Closed	-$15.5M	–	77
2023 Q4	$15.5M	Buy	+364,400	New	+$10.5M	1.55%	30
2021 Q2	–	Sell	-191,104	Closed	-$2.62M	–	213
2021 Q1	$2.62M	Hold	191,104	–	–	0.18%	115
2020 Q4	$3.17M	Sell	191,104 -532,000	-74%	-$6.91M	0.27%	76
2020 Q3	$7.56M	Buy	+723,104	New	+$7.63M	0.68%	55

Other funds holding CERE

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

BTI

Blue Trust Inc Alpharetta, Georgia $8.74B AUM 14.62% 1-Year Est. Return

Governors Lane's CERE Position: Q3 2024 in Review

Governors Lane sold out of Cerevel Therapeutics Holdings, Inc. Common Stock (CERE) in Q3 2024, closing a stake of 192,700 shares — an estimated $7.88M sold.

Governors Lane first reported a position in CERE in Q3 2020 and held it in 5 quarters. The position peaked at $15.5M in Q4 2023. 2 funds tracked by Wall St. Rank hold CERE as of Q3 2024.

Governors Lane reported no remaining Cerevel Therapeutics Holdings, Inc. Common Stock position as of Q3 2024 after selling out during the quarter.
Governors Lane sold 192,700 Cerevel Therapeutics Holdings, Inc. Common Stock shares in Q3 2024, an estimated $7.88M.
Governors Lane first reported a position in Cerevel Therapeutics Holdings, Inc. Common Stock in Q3 2020 and held it in 5 quarters.
Governors Lane's Cerevel Therapeutics Holdings, Inc. Common Stock position peaked at $15.5M in Q4 2023.
2 funds tracked by Wall St. Rank held Cerevel Therapeutics Holdings, Inc. Common Stock as of Q3 2024.

Based on Governors Lane's 13F filing for Q3 2024, filed 14 Nov 2024.